Amgen Inc.Long
AMGN - Increased Probability of Appreciation
Updated
AMGN has the support of Fiboclouds indicating an increased probability of appreciation at least until the first target. The second target should be tested, provided the stop loss is properly repositioned at the time of the first partial realization.
If this projection is confirmed and a partial realization occurs at the first target, the stop loss should be moved from its initial position to the same line where the position was opened.
This way, the journey towards the final target will proceed with reduced risk of losses and the preservation of the partial gains achieved so far.
Follow us to receive notifications of new trades as well as frequent updates on ongoing trades.
Finally, if you agree with the idea or found it useful, please give it a BOOST so that it can reach a larger number of people! Thank you!
If this projection is confirmed and a partial realization occurs at the first target, the stop loss should be moved from its initial position to the same line where the position was opened.
This way, the journey towards the final target will proceed with reduced risk of losses and the preservation of the partial gains achieved so far.
Follow us to receive notifications of new trades as well as frequent updates on ongoing trades.
Finally, if you agree with the idea or found it useful, please give it a BOOST so that it can reach a larger number of people! Thank you!
Trade closed: target reached
Intermediate target reached, resulting in a partial appreciation of +3.40% over 3 consecutive trading sessions.Action required: Move the stop loss up to 314.70, as outlined in our traditional risk management, and wait for the development towards the final target. This ensures the partial gain and exponentially reduces the risk of losses in this already successful and profitable trade.
Trade closed: target reached
AMGEN - Final Target Reached Resulting in Total Appreciation of +7.50% Over 7 Consecutive Trading Sessions
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.